Core Viewpoint - Amgen plans to invest over $600 million in a new center for science and innovation at its headquarters in Thousand Oaks, California, which is expected to create hundreds of jobs in the U.S. [1][5] Investment and Economic Impact - The new center aims to enhance collaboration among researchers, engineers, and scientists to accelerate the discovery of next-generation therapeutics [2] - Amgen has invested more than $40 billion in manufacturing and R&D in the U.S. since the Tax Cuts and Jobs Act (TCJA) of 2017, including over $5 billion in direct capital expenditures [3] - The enactment of pro-growth tax policies has facilitated Amgen's ability to invest domestically in cutting-edge science and manufacturing [3] Company Commitment and Future Plans - The new center will empower scientists with advanced tools and a collaborative environment to drive scientific excellence [4] - Construction is expected to begin in Q3 2025, further building on Amgen's recent investments, including a $900 million expansion in Central Ohio and a $1 billion investment for a second manufacturing plant in North Carolina [5] Company Background and Recognition - Amgen has been a pioneer in the biotechnology industry for over 40 years, focusing on innovative medicines for serious diseases [6] - The company has received accolades such as being named one of the "World's Most Innovative Companies" and "America's Best Large Employers" [7]

Company Overview - Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines to combat serious diseases [3] - The company has a broad and deep pipeline focused on treating cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3] - Amgen has been recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes in 2024 [4] Upcoming Events - Amgen will present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 9:00 a.m. ET [1] - Kave Niksefat, senior vice president of Global Marketing and Access, will be the presenter at the conference [1] - The presentation will be available via a webcast, which will also be archived for at least 90 days after the event [2]

Group 1 - Amgen will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2025, with key executives participating [1] - The webcast of the presentation will be available for the media, investors, and the public, and will be archived for at least 90 days [2] Group 2 - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with a strong pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3] - In 2024, Amgen received recognition as one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [4]